Viropro, Inc. (VPRO)

[PennyCrusher]

Just a quick response to your questions:

1) PIII did indeed fail overall, however it wasn't an abject failure.From reading the trial outcomes, Lucanix patients who had received prior radiotherapy and/or chemotherapy within 3 months showed a significantly prolonged survival - from about 16 months to 28 months. That's almost an 80% prolongation, an incredible result for patients with stage III/IV disease. To put that in context, Avastin confers about a 4% one year survival advantage, and sales are in the many billions per year. The study will need to be carried out again with the protocol updated. Yes, at a minimum it will take a couple years, but imagine the valuation if it were to succeed as expected?

2) Royston is only quoted as saying that cancer vaccines were 'dead as an investment'... in 2008! It's now about 6 years later and cancer immunotherapy has made significant strides. You think the next wave of cancer therapies are going to consist of carpet bombing the body with non-selective chemotherapeutic agents? Yeah right. Molecular targeting and cancer vaccines are the next wave that may finally turn the tide in this battle. The nearly $1 billion in federal funds poised to fund a new war on cancer will greatly accelerate progress in the field.